Safety Of Lubiprostone In Pediatric Patients With Functional Constipation: A Nonrandomized, Open-Label TrialⅡ
Dec 22, 2023
RESULTS
Demographics and Baseline Characteristics Demographic and baseline characteristics are summarized for the safety population in Table 1. The proportion of patients with a history of failed constipation treatment was comparable in the two treatment groups: 76.8% of patients in the lubiprostone 12-mcg BID group and 77.4% of patients in the 24-mcg BID group.

The most common concomitant medications were antihistamines for systemic use (26.4% of total patients), drugs for obstructive airway diseases (25.3% of total patients), and psychoanalytic (24.1% of total patients). A somewhat larger proportion of patients used antihistamines in the 12-mcg BID group (32.1%) than in the 24-mcg BID group (16.1%).

The use of drugs for obstructive airway diseases and of psychoanaleptics was comparable between the two treatment groups (obstructive airway diseases 26.8% and 22.6% and psychoanaleptics 21.4% and 29.0% in the 12-mcg BID and 24-mcg BID groups, respectively). In total, 13.8% of patients used rescue medication (16.1% in the lubiprostone 12-mcg BID group and 9.7% in the lubiprostone 24-mcg BID group). The most commonly received rescue medications were sennoside A þ B (5.7% of total patients) and bisacodyl (3.4% of total patients).
Safety
Treatment exposure was similar in both study groups. In the lubiprostone 12-mcg BID group and 24-mcg BID group, the median study medication exposure was 169.5 and 169.0 days, respectively; in the same treatment groups, total mean doses were 221.7 capsules and 206.1 capsules, respectively. Mean compliance with study medication was 73.3% in the lubiprostone 12-mcg BID group and 63.2% in the 24-mcg BID group. An overview of treatment-emergent AEs (TEAEs) is provided in Figure 1.

Of patients in the lubiprostone 12-mcg BID and 24-mcg BID groups, 57.1% and 48.4% reported 1 TEAE, respectively. Two serious TEAEs (6.5%) were reported in the lubiprostone 24-mcg BID group, and neither one (ulcerative colitis or worsening constipation) was drug-related. The proportions of patients discontinuing because of a TEAE were 12.5% and 16.1% in the lubiprostone 12-mcg BID group and 24-mcg BID group, respectively. Upper abdominal pain was the only TEAE leading to discontinuation (of 12 patients in total) that occurred in >1 patient. Most TEAEs in this study were of mild intensity and self-resolving.
Treatment-Related Adverse Events Reported in >–5% of Patients or Gastrointestinal Disorders Reported in >–3% of Patients
An overview of treatment-related adverse events (TRAEs) reported by 5% of patients is provided in Figure 2. Patients reported mostly GI disorders of diarrhea, followed by nausea, abdominal pain, and upper abdominal pain.

Treatment-Related Adverse Events Occurring in >1
Patient An overview of TRAEs occurring in >1 patient is provided in Table 2. Of patients in the lubiprostone 12-mcg BID and 24-mcg BID groups, 35.7% and 32.3%, respectively, reported TRAEs. Upper abdominal pain was the most commonly reported TRAE that led to discontinuation in the lubiprostone 12-mcg BID group (1.85%) and 24-mcg BID group (3.2%).

Subgroup Analyses of Treatment-Related Adverse Events
Female patients reported numerically higher TEAE rates (1 TEAE) than male patients in the 12-mcg BID group (21 females [65.6%] vs 11 males [45.8%]) as well as the 24-mcg BID group (10 females [58.8%] vs 5 males [35.7%]). White patients reported numerically higher TEAE rates (1 TEAE) than Black or other race patients in the 12-mcg BID group (White, 27 [62.8%]; Black, 4 [36.4%]; other race, 1 [50.0%]) as well as the 24-mcg BID group (White, 13 [52.0%]; Black, 2 [40.0%]; other race, none). In the 12-mcg BID group, 24 patients (61.5%), 7 patients (43.8%), and 1 patient (100.0%) reported 1 TEAE in the 6–9, 10– 13, and 14–17 years age groups, respectively. In the 24-mcg BID group, one patient (33.3%), seven patients (50.0%), and seven patients (50.0%) reported 1 TEAE in the 6–9, 10–13, and 14– 17 years age groups, respectively. Additionally, among patients who weighed 50 kg (ie, patients receiving the 24-mcg BID dose), the rates of TEAEs were numerically similar between patients weighing 50 to 60, >60 to <80 kg, and 80 kg, and did not indicate any clinically meaningful trends.

Subgroup Analyses of Treatment-Related Adverse Events
Female patients reported numerically higher TRAE rates (1 TRAE) than male patients in the 12-mcg BID group (13 females [40.6%] vs 7 males [29.2%]), as well as the 24-mcg BID group (7 females [41.2%] vs 3 males [21.4%]). In male patients, the most commonly reported TRAEs were: diarrhea, decreased blood uric acid, and dyspepsia, each in 8.3% of 12-mcg BID group patients; and diarrhea, upper abdominal pain, and irregular heartbeat, each in 7.1% of the 24-mcg group patients. In female patients, the most commonly reported TRAEs were nausea and diarrhea in 12.5% and 11.8% of patients in the 12-mcg and 24-mcg BID groups, respectively. In the 12-mcg BID and 24-mcg BID groups, TRAEs 1 were reported in 17 (39.5%) and 8 (32.0%) of White patients, and 3 (27.3%) and 2 (40.0%) of Black patients, respectively. In the 24-mcg group, the most commonly reported TRAE in White patients was diarrhea (12.0%).
The most commonly reported TRAE by Black patients in the 12-mcg BID group was headache (18.2%); however, Black patients in the 24-mcg BID group reported abdominal pain, upper abdominal pain, decreased appetite, and back pain, each in 20.0% of patients. None of the other race patients reported 1 TRAE. In the 12-mcg BID group, 17 (43.6%), 3 (18.8%), and none of the patients in the 6–9, 10–13, and 14–17 years age groups, respectively, reported 1 TRAE. In the 24-mcg BID group, no patients, 5 patients (35.7%), and 5 patients (35.7%) in the 6–9, 10– 13, and 14–17 years age groups, respectively, reported 1 TRAE. The most commonly reported TRAE in the 6–9 years age category was nausea (10.3%) in the 12-mcg BID group.
TRAEs in the 12- mcg BID group in patients ages 10–13 years were reported by one patient (6.3%), and included diarrhea, abdominal distension, upper abdominal pain, dyspepsia, headache, and epistaxis; in the 24-mcg BID 10–13 years age group, TRAEs were reported by one patient (7.1%), and included diarrhea, upper abdominal pain, anaphylactoid reaction, increased alanine aminotransferase, and headache. The most commonly reported TRAEs in patients ages 14–17 years were upper abdominal pain and diarrhea, each reported in 14.3% of patients in the 24-mcg group.
Clinical Laboratory Parameters
Minimal to no variations were observed in blood chemistry hematology or urinalysis parameters. No noticeable change from baseline to week 25 was observed for sodium (ranged from mean 137.9 mmol/L, 95% confidence interval (CI) [137.4, 138.37] to 139.4 mmol/L, 95% CI [138.8, 140.1]; reference range 133– 145 mmol/L) or potassium (ranged from mean 4.0 mmol/L, 95% CI [3.9, 4.1] to 4.2 mmol/L, 95% CI [4.1, 4.3]; reference range 3.4– 5.2 mmol/L). There were no cases of electrolyte abnormalities in the study participants, even in children who reported having diarrhea, and no actions were necessary for any electrolyte derangements.

In addition, the liver function markers-albumin, alkaline phosphatase, alanine aminotransferase, aspartate transaminase, and bilirubin (direct and total)-did not indicate any clinically meaningful trends. Minimal to small variations were observed from baseline in physical examinations and vital sign parameters that included height, weight, body mass index, heart rate, systolic blood pressure, and diastolic blood pressure; there were no TEAEs related to variations in systolic or diastolic blood pressure observed.
Exploratory
Efficacy Assessment The efficacy of lubiprostone in PFC was assessed by the investigators as moderately to quite a bit effective. At week 12, the mean lubiprostone 12-mcg BID group grading was 2.8 and the mean 24-mcg BID group grading was 2.9 (on a scale of 0 to 4). At week 24, the mean lubiprostone 12-mcg BID group grading was 2.7 and the mean 24-mcg BID group grading was 2.2.
Natural Herbal Medicine For Relieving Constipation-Cistanche
Cistanche is a genus of parasitic plants that belongs to the family Orobanchaceae. These plants are known for their medicinal properties and have been used in Traditional Chinese Medicine (TCM) for centuries. Cistanche species are predominantly found in arid and desert regions of China, Mongolia, and other parts of Central Asia. Cistanche plants are characterized by their fleshy, yellowish stems and are highly valued for their potential health benefits. In TCM, Cistanche is believed to have tonic properties and is commonly used to nourish the kidney, enhance vitality, and support sexual function. It is also used to address issues related to aging, fatigue, and overall well-being. While Cistanche has a long history of use in traditional medicine, scientific research on its efficacy and safety is ongoing and limited. However, it is known to contain various bioactive compounds such as phenylethanoid glycosides, iridoids, lignans, and polysaccharides, which may contribute to its medicinal effects.

Wecistanche's cistanche powder, cistanche tablets, cistanche capsules, and other products are developed using desert cistanche as raw materials, all of which have a good effect on relieving constipation. The specific mechanism is as follows: Cistanche is believed to have potential benefits for relieving constipation based on its traditional use and certain compounds it contains. While scientific research specifically on Cistanche's effect on constipation is limited, it is thought to have multiple mechanisms that may contribute to its potential to relieve constipation. Laxative Effect: Cistanche has long been used in Traditional Chinese Medicine as a remedy for constipation. It is believed to have a mild laxative effect, which can help promote bowel movements and induce constipation. This effect may be attributed to various compounds found in Cistanche, such as phenylethanoid glycosides and polysaccharides. Moistening the Intestines: Based on traditional use, Cistanche is considered to have moisturizing properties, specifically targeting the Intestines. Promoting hydration and lubrication of the Intestines may help soften tools and facilitate easier passage, thereby relieving constipation. Anti-inflammatory Effect: Constipation can sometimes be associated with inflammation in the digestive tract. Cistanche contains certain compounds, including phenylethanoid glycosides and lignans, that are believed to have anti-inflammatory properties. By reducing inflammation in the intestines, it may help improve bowel movement regularity and relieve constipation.






